MedTrace Logo

Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects

NCT01402128 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-12-25

Study results available
· View outcomes & findings →

Summary

Barley, like oats, is a rich source of the soluble fibre β-glucan, which has been shown to significantly lower LDL-cholesterol (LDL-C). However, barley foods have been less widely studied.

Conditions

  • Overweight; Hyperlipidemia

Interventions

DIETARY_SUPPLEMENT

Barley beta-glucan(3.0g)

Barley beta-glucan(3.0g/day) for 12 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo for 12 weeks

Sponsors & Collaborators

  • Chonbuk National University Hospital

    lead OTHER

Principal Investigators

  • Soo-Wan Chae, MD., PhD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-10-31
Completion
2011-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01402128 on ClinicalTrials.gov